Some of these are very promising indeed and the current mood in MS research is very optimistic - we can look forward to more effective treatments in the near future.
However I will deal with these in a later section - in this section I will concentrate on the so-called "ABC" treatments and steroids. These are not the only treatments for MS - there are many treatments for the specific symptoms such as spasticity, vertigo, fatigue or depression and I will deal with them in the next section.
Here I want to look at treatments that affect the process of demyelination and control of relapses.
ABC Treatments
Perhaps the most effective treatments currently available today deal with the autoimmune component of multiple sclerosis and work by regulating aspects of the immune system. They are known as the "ABC" treatments, where "A" stands for Avonex, "B" stands for Betaseron/Betaferon and "C" stands for Copaxone.
Avonex and Betaseron are both varieties of beta interferon. A third drug, Rebif, is also beta interferon. ABCR would be a more accurate acronym though clearly less appealing to those of us with a crossword-solving mentality.
Copaxone is a completely different drug altogether - the active ingredient being glatiramer acetate, Co-polymer-1 or COP-1.
A fifth drug, Novantrone, has recently become available. This is a chemotherapeutic agent which I shall deal with in a later section.
Beta interferon
Beta Interferon comes in two varieties, beta interferon-1a (Avonex and Rebif) and beta interferon-1b (Betaseron in the US and Betaferon in Europe).
Beta interferon (IFN-b) is a naturally occuring biochemical in the human body and belongs to a group of biochemicals known as interferon's (IFNs) which regulate the functioning of the immune system.
The mechanism by which IFN-b functions is complex and not fully understood. I shall explore this more fully in a later section but for now we can summarize it as:
It reduces the levels of another interferon, called interferon gamma (IFN-g), which is known to be associated with the disease process in multiple sclerosis.
It appears to block certain white blood cells from attacking the insulating sheaths of the nerves - the myelin sheaths.
It appears to stop a type of white blood cell, called a T Cell, from releasing immune system signaling molecules (cytokines) that would otherwise encourage inflammation.
It appears to interfere with the process of summoning new immune system cells to the site of inflammation.
Read more to come: